PATHOLOGY SLIDE REVIEW:
THE MOST IMPORTANT PART OF A SECOND OPINION
The diagnosis written in your report is one pathologist's interpretation of your tissue. An expert slide review is a second pathologist reading the same tissue — and reaching their own independent conclusion.
analyticsAt a Glance
- check_circlePathological diagnosis is changed or refined in 15–25% of cancer second opinion cases
- check_circleA pathology report alone is not sufficient — the reviewing pathologist must examine the original slides
- check_circleSubspecialist pathologists (sarcoma, lymphoma, neuro-oncology) identify features that generalist pathologists may not recognise
- check_circleCancerFax arranges expert pathology slide review with sub-specialist pathologists at leading diagnostic centres
What Is Pathology Slide Review?
Pathology slide review is the re-examination of your original cancer tissue specimens — either glass slides prepared from your biopsy or surgery, or digital whole-slide images scanned from those slides — by a pathologist other than the one who made the original diagnosis. The reviewing pathologist forms an independent opinion based on what they observe in the tissue, not based on what the first pathologist concluded.
“Pathology is not a machine output — it is expert human interpretation of biological material. Two experts can examine the same tissue and reach different, clinically consequential conclusions.”
What the Pathologist Reviews
H&E-stained slides for tumour morphology and grade; immunohistochemistry (IHC) slides showing protein expression (ER, PR, HER2, PD-L1, CD markers, etc.); FISH results for gene amplification; and molecular/genomic data if available. A comprehensive review may trigger additional stains or molecular tests not performed originally.
Why a Report Alone Is Not Enough
A pathology report describes the first pathologist's conclusions — it does not allow a second expert to independently examine the tissue. Just as a radiologist must look at the actual scan rather than another radiologist's description of it, a pathologist must review the actual slides to form an independent view.
How Often Slide Review Changes the Diagnosis
Multiple published studies quantify the frequency of diagnostic discordance in pathology second opinion — the numbers are consistent and striking across cancer types.
- 15–25%Cases where diagnosis is changed or refined on expert slide reviewAcross published series from specialist cancer centres, pathological diagnosis is meaningfully changed — including grade, subtype, or primary site — in 15–25% of second opinion cases.
- 60%+Discordance rate in sarcoma and rare tumour pathology reviewsFor soft tissue sarcoma specifically, expert pathology review at reference centres reveals discordance with the original diagnosis in over 60% of referred cases — the highest of any major cancer type.
- 1 in 10Cases where an entirely different cancer type is identifiedIn approximately 10% of second opinion pathology cases, the tumour type is changed entirely — e.g., what appeared to be a carcinoma is identified as lymphoma, or a presumed primary tumour is identified as metastatic — dramatically altering the treatment approach.
What Expert Slide Review Can Identify That Reports Miss
The most clinically impactful findings from expert pathology review fall into several categories — each with direct treatment consequences.
| Finding Type | Example | Treatment Impact |
|---|---|---|
| Grade change | Grade 2 → Grade 3 glioma; grade 1 → grade 2 meningioma | More aggressive treatment required; different RT dose; different systemic therapy indication |
| Subtype reclassification | Adenocarcinoma → squamous cell (lung); DLBCL → Burkitt lymphoma | Completely different chemotherapy regimen; different response rates; eligibility for different trials |
| Primary site identification | Metastatic carcinoma of unknown primary correctly identified as thyroid or colorectal origin | Primary-site-directed targeted therapy becomes available; prognosis changes significantly |
| Missed molecular marker | HER2 overexpression not detected on original IHC; ALK rearrangement missed; MSI-H not reported | Eligibility for trastuzumab, crizotinib, or pembrolizumab depends on these markers — missing them means missing the treatment |
| Rare or specialist-dependent diagnosis | GIST misclassified as leiomyosarcoma; low-grade fibromyxoid sarcoma misclassified as benign fibroma | GIST: imatinib is highly effective; leiomyosarcoma: imatinib has no role — the difference is life-altering |
| Tumour in margins misread as clear | Positive surgical margins called clear on original review | Re-excision or adjuvant RT required to prevent recurrence — missed margin leads to undertreated disease |
How Pathology Slide Review Works Through CancerFax
The CancerFax pathology review process is structured to ensure the reviewing pathologist has everything needed to form a comprehensive, independent opinion — including performing additional tests where the original panel was incomplete.
- 1
Tissue Request and Retrieval
CancerFax provides a standardised pathology release request letter. Patient submits it to their original hospital's pathology department requesting glass slides, unstained cut sections, and the paraffin-embedded FFPE block.
- 2
Slide Shipment to Review Centre
CancerFax coordinates international shipment of physical slides via specialist medical specimen couriers with appropriate customs documentation. Digital whole-slide scan upload is arranged where hospitals have scanning capability.
- 3
Initial Quality Assessment
The reviewing pathology centre assesses slide quality and tissue quantity. If additional stains or molecular testing are required to complete the review (e.g., IHC for a missed marker), these are performed from unstained sections at this stage.
- 4
Expert Subspecialist Review
A pathologist with subspeciality expertise in your specific cancer type independently examines all slides, reviews original stains, and interprets any additional tests performed. The subspeciality match is the critical differentiator — a sarcoma pathologist reviews sarcoma cases; a neuropathologist reviews brain tumour cases.
- 5
Pathology Report and Clinical Integration
A formal written pathology second opinion report is issued in English, covering diagnostic findings, molecular marker results, discordance with original diagnosis (if any), and clinical implications. The report is integrated with the oncologist's second opinion if a full treatment review is also requested.
Generalist Pathologist vs Subspecialist Cancer Pathologist
Not all pathologists have equal expertise in all cancer types. The value of a specialist pathology review comes specifically from subspeciality training and high case volume in the relevant tumour type.
General / Community Pathologist
- Reviews all tumour types across body sitesA general pathologist may see 5–10 sarcoma cases per year — insufficient volume to develop the pattern recognition required to distinguish 50+ sarcoma subtypes reliably.
- May not perform full IHC panels for rare subtypesWithout subspeciality knowledge of which markers are required for a specific rare tumour, the IHC panel ordered may be incomplete — leaving key diagnostic information unaddressed.
- Excellent for common tumours in routine practiceGeneral pathologists provide excellent diagnoses for common, histologically straightforward cancers — the limitation is specifically in rare, morphologically ambiguous, or molecularly complex tumours.
Subspecialist Cancer Pathologist
- Reviews hundreds of cases per year in their tumour typeVolume produces pattern recognition — a sarcoma subspecialist reviewing 300 cases per year recognises subtle morphological features and IHC patterns that lower-volume pathologists will not have encountered.
- Knows exactly which additional tests are neededSubspecialist pathologists are aware of the latest WHO classification criteria, required molecular markers, and diagnostic algorithms specific to their tumour type — and will order appropriate additional testing proactively.
- Integrates molecular, clinical, and imaging contextThe best subspecialist reviews are not just a pathology read — they incorporate clinical context, imaging findings, and molecular data to produce an integrated diagnostic opinion.
Frequently Asked Questions
Common questions about pathology slide review as part of a cancer second opinion.
About Pathology Review
Can I get a pathology review without a full second opinion?
Yes — CancerFax offers pathology-only review as a standalone service for patients who want to confirm their diagnosis before deciding whether to pursue a full treatment second opinion. This is particularly useful when the diagnosis itself is uncertain or when a rare tumour type requires specialist confirmation before treatment begins.
What if the reviewing pathologist cannot make a definitive diagnosis from the available tissue?
This can occasionally occur if tissue quantity is very limited or slide quality is poor. In this case, the reviewing pathologist will specify what additional material is needed — typically a repeat biopsy or additional unstained sections cut from the paraffin block. CancerFax will communicate this clearly and help coordinate the additional material request.
Will my original slides be returned after review?
Yes — this is standard practice. The reviewing pathology centre will retain unstained cut sections (which are consumed in additional testing) but will return original stained slides and the paraffin block to your original hospital. CancerFax coordinates return shipment as part of the service.
Is digital pathology (whole-slide imaging) as good as reviewing physical glass slides?
For most diagnostic purposes, high-resolution whole-slide imaging is equivalent to glass slide review and is increasingly used at reference centres globally. It eliminates courier delays and slide damage risk. CancerFax will advise whether your case can be managed digitally or requires physical slide shipment based on the specific diagnostic question and the reviewing centre's capabilities.
More from the Cancer Second Opinion Resource Library
Continue exploring the complete second opinion guide — from getting records to remote vs in-person decisions.
- ↑ Cancer Second Opinion — Complete Guide
- What Is a Cancer Second Opinion and Why Should Every Patient Consider One?
- How Often Do Second Opinions Change Diagnosis or Treatment Plan?
- How to Get Your Medical Records for an International Second Opinion
- Remote vs In-Person Cancer Second Opinions: How to Decide
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Arrange an Expert Pathology Slide Review Through CancerFax
CancerFax organises pathology slide review with subspecialist cancer pathologists at leading diagnostic centres in India, China, and internationally — including additional molecular and IHC testing where required. Reports are delivered in English within 7–14 business days.
This content is for informational purposes only and does not constitute medical advice. A pathology review is a supplementary expert review — your treating team remains responsible for clinical decisions.